When Drug Pricing Becomes Trade Policy

For years, pharmaceutical companies could treat U.S. reimbursement, European market access, trade policy and manufacturing strategy as related but mostly separate issues. That separation is becoming harder to defend.

The Administration has linked U.S. drug prices to prices paid abroad, pursued voluntary most favored nation agreements, proposed international benchmarks in Medicare, and tied pharmaceutical tariff treatment to both pricing and domestic manufacturing commitments. The important change is not simply that the United States wants lower drug prices.

Foreign reimbursement systems and manufacturing choices are now being pulled into U.S. trade policy. The Supreme Court held in February 2026 that IEEPA does not authorize the President to impose tariffs.

The Administration responded by preserving and expanding other statutory tools. Section 232 is being used against patented pharmaceutical imports and Section 301 is being used to examine foreign pharmaceutical pricing practices.

FDA is also using the Commissioner’s National Priority Voucher (CNPV) program to connect regulatory timing with priorities that include domestic manufacturing and supply chain resilience.

The United Kingdom shows the negotiated path. Germany shows the enforcement path.1-6,13

C SUITE TAKEAWAY

Management should ask more than “What does this reimbursement rule require?” The better question is “How does this pricing, launch, manufacturing or market access decision change our exposure under U.S. payment policy and trade law?”

Seven developments define the current landscape

1. Most Favored Nation (MFN) pricing has moved from policy idea to announced company agreements. The White House says it has announced 17 agreements with major pharmaceutical manufacturers designed to bring U.S. prices closer to those paid in other developed countries.7
2. GLOBE and GUARD are still proposed CMS models. They are not final rules. They matter because they show how international prices could become inputs into Medicare Part B and Part D payment policy.8,9
3. The proposed GLOBE and GUARD rules would exclude a drug while a Medicare Maximum Fair Price is in effect. That reduces the direct IRA versus MFN conflict earlier versions of this paper anticipated.8,9
4. In February 2026, the Supreme Court held that IEEPA does not authorize the President to impose tariffs. The same day, the White House expressly stated that the rollback did not affect duties imposed under Sections 232 or 301.1,2
5. The post decision response was immediate. USTR announced accelerated Section 301 investigations, specifically identifying pharmaceutical pricing practices as an area of concern, while the Administration maintained Section 232 tariffs and investigations.3
6. On April 2, 2026, the President imposed Section 232 tariffs on patented pharmaceuticals and associated ingredients, with tariff treatment linked to trade deals, onshoring plans and MFN pricing agreements. In June, USTR opened a Section 301 investigation into Germany’s alleged underpayment for innovative medicines. Together, those actions show a coordinated two statute strategy directed at both supply chains and foreign pricing systems.4,5
7. FDA is also adding regulatory speed to the manufacturing equation. The CNPV program can accelerate review for selected products that advance priorities including domestic manufacturing and supply chain resilience or affordability. FDA describes a target review timeline of one to two months and lists multiple approvals under the program in 2026.13

Drug Pricing is Becoming an Enterprise Risk

The old line between reimbursement policy and corporate strategy is fading. The change is easy to describe. A pricing concession in one country can affect an international benchmark.

A launch delay can change which country becomes a reference point. A manufacturing location can change tariff exposure or government leverage.

A market access decision that once looked local can now affect U.S. revenue assumptions. Consider a simple example in which a manufacturer launches a drug in Europe at a lower negotiated price.

That price could later become relevant to a U.S. international benchmark. The same company may manufacture the drug outside the United States, creating a separate tariff question.

Two decisions made by different teams can now affect the economics of the same product. This does not mean every European price automatically becomes a U.S. price or every foreign reimbursement decision becomes a trade violation. The rules differ by program, product and country.

Some U.S. models remain proposed, and the Germany investigation has not produced a final finding. The direction is nevertheless clear: U.S. policymakers are using international price comparisons, company agreements, and trade authorities to influence pharmaceutical economics at home and abroad.

Therefore, management cannot leave drug pricing only to market access, trade only to customs counsel, manufacturing only to operations, or government affairs only to monitoring. Senior leaders need one view of how a decision in one part of the company can move value or risk somewhere else.

MANAGEMENT IMPLICATION

The strategic advantage is understanding what a price or manufacturing decision in one market can do to the rest of the company.

What Changed After the Supreme Court?

The Supreme Court narrowed one tariff pathway. The Administration then turned more heavily to laws that specifically authorize trade action. [Primary source anchors: Supreme Court,1 White House,2 USTR.3]

On February 20, 2026, the Supreme Court held in Learning Resources, Inc. v. Trump, together with Trump v. V.O.S. Selections, Inc., that IEEPA does not authorize the President to impose tariffs. The Court’s ruling matters because it rejected the use of a broad emergency economic statute as tariff authority.

It did not hold that the President lacks all tariff authority. Congress has separately delegated trade powers through other statutes.1

The Administration made its response explicit. On the day of the decision, the White House ended the IEEPA tariff actions at issue while stating that duties imposed under Section 232 of the Trade Expansion Act and Section 301 of the Trade Act were not affected.

USTR separately announced that it would initiate several accelerated Section 301 investigations and specifically identified pharmaceutical pricing practices as a target area.2,3

Section 122 served as a temporary bridge through a 150-day import surcharge tied to balance of payments concerns, but pharmaceuticals and pharmaceutical ingredients were exempt. The more durable pharmaceutical story is the Administration’s move toward Sections 232 and 301.2

What Do Sections 232 and 301 Actually Do?

Section 232 focuses on the product: where it comes from and whether imports threaten national security. On April 2, 2026, the President used it to impose a 100% baseline tariff on covered patented pharmaceuticals and associated ingredients, with different rates for trade deal countries and preferential treatment for companies with approved U.S. manufacturing plans or MFN pricing agreements.

The proclamation links tariff treatment, MFN pricing and domestic manufacturing. Section 301 focuses on the foreign government: whether its acts, policies or practices may be unreasonable, discriminatory or burdensome to U.S. commerce.

On June 18, USTR used that authority to open the Germany pharmaceutical pricing investigation.4,5 The legal novelty is not that Sections 232 and 301 are new statutes.

Both have long histories and established procedures. What has not yet been squarely tested by the Supreme Court is this coordinated post Learning Resources use of statute specific trade authorities to recreate leverage that had previously been asserted through IEEPA, especially when pharmaceutical pricing, reimbursement, market access, and onshoring are treated as parts of one trade strategy.

That does not mean the architecture is unlawful. It means companies should treat litigation risk and statutory fit as part of the strategic analysis rather than assume the new scheme has already received judicial approval.

THE LEGAL POINT

The post IEEPA strategy is not simply “more tariffs.” Section 232 pressures products, manufacturing, and supply chains through a national security theory. Section 301 pressures foreign government practices through an unfair trade theory. Used together, they create leverage on both the company and the country. The statutes are established. Their coordinated pharmaceutical use in this form is still developing.

Regulatory Speed Adds Another Dimension to U.S. Manufacturing Decisions

Trade policy is not the only way the federal government is influencing pharmaceutical manufacturing decisions. FDA is also using regulatory incentives that may change how management evaluates the economics of producing medicines in the United States.13

The CNPV program is designed to accelerate review of selected drugs and biologics that advance defined U.S. health priorities. Those priorities include domestic manufacturing and supply chain resilience, affordability, unmet medical need and important medical innovation.

FDA describes a target review timeline of one to two months for selected applications, compared with six months or more under other priority review programs.13 For management teams, the important point is the value of time.

A U.S. manufacturing decision has traditionally been evaluated against construction costs, labor, taxes, supply chain reliability, and access to the U.S. market. Regulatory timing can now become another part of that calculation.

A company considering U.S. manufacturing should therefore ask whether the location of manufacturing could affect more than tariff exposure and supply chain risk. If a product can qualify for CNPV review, faster regulatory timing may also affect launch planning, revenue timing and the value of the asset. FDA lists multiple approvals under the program in 2026.13

A company should not move manufacturing simply to pursue a voucher. CNPV eligibility depends on the product and the program criteria, and manufacturing investments remain long term decisions. The program does give CEOs and boards another variable to consider when comparing U.S. manufacturing with alternatives elsewhere.

THE MANAGEMENT IMPLICATION

For companies already evaluating U.S. manufacturing capacity, regulatory timing belongs in the same discussion as construction costs, labor, taxes, tariff treatment and supply chain resilience. CNPV does not change the need for a sound manufacturing business case. It gives management another factor to consider when comparing U.S. manufacturing with alternatives elsewhere.13

How MFN Is Being Put into Practice

There is not a single MFN program, as the Administration is using several different approaches that connect prices paid abroad with U.S. pricing policy. The current MFN approach began with Executive Orders in April and May 2025 directing federal agencies to lower prescription drug prices and pursue prices for Americans that more closely reflect prices available in comparable developed countries.10

Since then, the White House says it has announced 17 MFN agreements with major pharmaceutical manufacturers. Those agreements, TrumpRx and related pricing initiatives show that the Administration is using several tools at once: negotiation, public pressure, federal payment policy, market access programs and trade leverage.7,11

GLOBE: Proposed international benchmarking for Part B

GLOBE is a proposed mandatory CMS Innovation Center model for certain Medicare Part B drugs. As proposed, manufacturers would owe rebates when U.S. prices exceed an international benchmark.

CMS currently anticipates an October 1, 2026, start, subject to a final rule.8 One point is especially important. GLOBE would not simply stack a lower international price on top of an IRA negotiated price.

The proposal would exclude a Part B drug while an IRA Maximum Fair Price, or MFP, is in effect. The challenge is therefore managing different pricing systems at different points in a product’s life, not choosing the lower of two federal prices.8

GUARD: Proposed international benchmarking for Part D

GUARD is a proposed mandatory CMS Innovation Center model for certain Medicare Part D drugs. If finalized, CMS anticipates a January 1, 2027, start. Like GLOBE, GUARD would use rebates tied to prices paid in economically comparable countries.9

GUARD would also exclude a drug while an MFP is in effect. International pricing can still affect U.S. economics before or after that period, so management needs to know which program applies when and how an earlier pricing decision may affect the product later.9

GENEROUS: Medicaid and international net prices

GENEROUS works differently—it is a voluntary Medicaid model launched in January 2026. Participating manufacturers provide supplemental rebates intended to align Medicaid net prices with what selected other countries pay, while participating states use standardized coverage rules.12

For executives, the acronym is not the important part. The larger point is that international price comparisons are becoming more common inside U.S. healthcare policy while trade policy is simultaneously being used to pressure foreign pricing and manufacturing behavior. Payment and trade are now moving on parallel tracks.

WHAT NOT TO DO

Do not treat GLOBE, GUARD, and GENEROUS as one unified “MFN rule.” They work differently, apply to different populations and are at different stages. The C-suite needs a product-by-product map, not one slogan.

The United Kingdom: Pricing as the Price of Trade Accommodation

The UK shows how reimbursement policy and tariff policy can be negotiated together [Primary source anchor: UK Government].6

The U.S. and UK pharmaceutical arrangement is one of the clearest examples of reimbursement, MFN policy and trade law being negotiated together. Under the arrangement published April 2, 2026, the UK committed to increase the net NHS price paid for prospective new medicines by 25% beginning in April 2026, increase spending on new medicines over time, modify NICE access economics and cap specified VPAG repayment rates.6

In return, the United States committed to protect qualifying UK pharmaceutical products from Section 232 tariffs through January 19, 2029, provided specified company MFN and tariff agreement conditions are met, and to refrain from additional Section 301 pharmaceutical tariffs during the stated period. The arrangement also expressly references GENEROUS and anticipated GLOBE and GUARD protections intended to reduce launch disincentives in a lower priced market.6

The significance is straightforward. The arrangement does not treat drug prices, patient access, supply chain resilience, MFN, Section 232 and Section 301 as separate policy files. It puts them in the same bargain. That is the architecture this analysis is describing.

What a CEO should see in the UK example

• A country’s reimbursement system can become part of a broader economic negotiation.
• Tariff protection can depend on company behavior and government pricing commitments.
• Governments are now paying attention to launch incentives because a low launch price can affect international reference models.
• A country’s expected revenue is only one factor in a market access decision.

THE DEEPER LESSON

The UK arrangement is the negotiated version of the new framework: price and access commitments on one side, tariff and launch protections on the other. For global manufacturers, market access and trade strategy need to be managed together.

Germany: Section 301 Turns Reimbursement into Trade Enforcement

Germany shows how the same policy shift can reach a foreign reimbursement system. [Primary source anchor: USTR].5

On June 18, 2026, USTR opened a Section 301 investigation into Germany’s alleged “persistent underpayment” for innovative pharmaceutical products. In simple terms, USTR is asking whether German pricing and reimbursement practices are unreasonable or discriminatory and burden or restrict U.S. commerce.

Those are allegations being investigated, not final legal findings.5 The investigation is still underway.

Written comments were due August 10, 2026, and USTR has scheduled a public hearing for September 22, 2026. The process can end without tariffs, through findings and responsive action, or through a negotiated resolution.5

The larger point goes beyond Germany. Section 232 can pressure where and how pharmaceutical companies manufacture. S

ection 301 can pressure how foreign governments pay for medicines. Germany therefore supplies the second half of the coordinated strategy that the April Section 232 proclamation began to make concrete.4,5

A CAUTION FOR MANAGEMENT

Do not assume the Germany investigation means tariffs are inevitable. Section 301 is a process. Management should assume, however, that foreign pharmaceutical pricing policy can now lead to U.S. trade scrutiny, political pressure, and, potentially, responsive action.

Five Questions the C Suite Should Ask Now

The objective is to turn policy complexity into decision discipline.

1. Where should we launch, and in what order? Launch sequencing now affects more than time to revenue. Management should ask whether a launch price in one market could influence an international benchmark, affect another government negotiation or change the economics of entering a lower priced market.
2. Which international prices create U.S. exposure? The company should know which products, countries and net price arrangements could matter under GLOBE, GUARD, GENEROUS, voluntary MFN commitments or future federal models. Where a policy looks to net pricing, the analysis should include confidential rebates and not just public list prices.
3. What happens if another country “becomes Germany?” Every major market access strategy should be tested for two questions: what does this mean locally, and could U.S. policymakers view the system as unfair to U.S. commerce?
4. How does manufacturing location change our options? Section 232 makes manufacturing location, country of origin and domestic manufacturing commitments relevant to tariff treatment. CNPV adds a separate regulatory consideration because domestic manufacturing and supply chain resilience are among the priorities that can support accelerated review for selected products. Section 301 remains relevant where a foreign government’s reimbursement system becomes a trade issue. Management should model what the company controls, what regulatory incentives may be available and what a government partner may be pressured to change.13
5. Who inside the company makes sure these decisions connect? If legal, market access, finance, government affairs, trade and supply chain teams optimize separately, the company may create global exposure while making a locally rational decision. Senior management needs a process that forces those perspectives into the same room before a material commitment is made.

How Management Can Put the Pieces Together

The goal is simple: give management one way to see how pricing, trade, manufacturing and market access decisions connect. Management does not need to predict every final rule.

It needs a repeatable way to test major decisions against a changing set of legal and commercial risks. We recommend building one cross border pricing and trade exposure map around the company’s major products and pipeline assets.

The transaction and investment lens

This same framework should be used in acquisitions, licensing deals and major capital projects. A product’s pricing history, European launch sequence, manufacturing footprint and government commitments can affect future value even when they do not stand out in a traditional healthcare regulatory review. Investors and boards should ask whether those factors add value, limit flexibility or create a risk that has not been modeled.

What Management Teams Should Do in the Next 90 Days

The current environment favors preparation over prediction. Build one enterprise exposure map. Do not maintain separate U.S., UK, and EU trade analyses that never connect. Put the major products, markets, prices, rebates, launch dates and manufacturing locations on one decision map.

Revisit launch sequencing assumptions. Identify lower priced markets that could affect an international benchmark or a government negotiating position. Consider whether timing, sequencing, or a different contract structure changes the economics.

Stress test the UK and Germany scenarios. Ask what the company would do if a key market were offered a UK style accommodation, faced a Germany style Section 301 investigation, or saw its pharmaceutical exports subjected to Section 232 leverage.

Review the manufacturing footprint through a trade and regulatory lens. For each critical patented product and ingredient, identify country of origin, applicable Section 232 treatment, domestic manufacturing commitments, trade deal status, alternative sourcing and the financial cost of a tariff or policy change.

For products tied to current or planned U.S. manufacturing, assess whether CNPV eligibility or regulatory timing should be part of the investment analysis.13

Set a senior escalation rule. Major pricing, launch and manufacturing decisions should trigger a cross functional review before the company gives up flexibility that may be valuable in another market. Monitor the rules that can change the map.

GLOBE and GUARD remain proposed, the Germany Section 301 process is ongoing, and the pharmaceutical Section 232 regime contains country and company specific conditions. Management should plan around the current landscape while keeping enough flexibility to update assumptions as rules, agreements, enforcement actions, and litigation evolve.

BOARD LEVEL QUESTION

Can management explain, on one page, how a major pricing decision in Europe could change U.S. reimbursement, trade, manufacturing and valuation exposure? If not, the company probably does not yet have one enterprise view of the risk.

Conclusion

Drug pricing has entered a new phase. Foreign pharmaceutical prices are now part of more than a domestic affordability debate.

International prices appear in federal payment models and manufacturer agreements, while pharmaceutical pricing, manufacturing and market access have become subjects of bilateral trade negotiation and statutory trade enforcement.

The Supreme Court’s Learning Resources decision removed IEEPA as the tariff authority the Administration had been using. The policy response was not retreat.

The White House expressly preserved Sections 232 and 301, USTR announced new Section 301 investigations that included pharmaceutical pricing, the President imposed a pharmaceutical Section 232 regime in April, and USTR opened the Germany pharmaceutical pricing investigation in June.1-5

For CEOs, CFOs, general counsel and commercial leaders, the most important development may be the structure that emerges from those actions. Section 232 can link tariff treatment to manufacturing, domestic investment and MFN commitments.

Section 301 can convert a foreign reimbursement policy into a U.S. trade dispute. CNPV adds regulatory timing to the manufacturing decision by making domestic manufacturing and supply chain resilience relevant to accelerated review eligibility for selected products.

Together, these tools can affect company decisions, government policy and the economics of where a product is developed, manufactured and launched.13

The statutes themselves are not new, and this paper does not assume that a court would uphold or invalidate every future application. The unresolved issue is how far this coordinated use of Sections 232 and 301 can go when tested against the language, procedures and limits of Sections 232 and 301.

Companies should not wait for that litigation to be resolved before understanding their exposure. The better approach is to see the connections before the commercial decision is made. That is where policy foresight becomes business strategy.

About the Author

Ron Lanton, Senior Partner & Global Strategist at Lanton, Lanton & Sosa Law PLLC.

References

The following primary government sources support the principal legal and policy developments discussed in this paper. They are included so readers can independently verify the underlying events. All were current as of August 14, 2026.

1. Supreme Court of the United States. Learning Resources, Inc. v. Trump; Trump v. V.O.S. Selections, Inc. Opinion issued February 20, 2026. supremecourt.gov
2. The White House. Ending Certain Tariff Actions; Imposing a Temporary Import Surcharge to Address Fundamental International Payments Problems. Published February 20, 2026. whitehouse.gov
3. Office of the US Trade Representative. Ambassador Greer Issues Statement on Supreme Court IEEPA Decision. Published February 20, 2026. ustr.gov
4. The White House. Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States. Published April 2, 2026. whitehouse.gov
5. Office of the US Trade Representative. USTR Announces Initiation of Section 301 Investigation of Germany’s Persistent Underpayment for Innovative Pharmaceutical Products. Published June 18, 2026. ustr.gov
6. Government of the United Kingdom. Arrangement Between the United States of America and the United Kingdom on Pharmaceutical Pricing. Published April 2, 2026. gov.uk
7. The White House. Fact Sheet: Expansion of TrumpRx.gov and 17 Most-Favored-Nation Drug Pricing Agreements. Published May 18, 2026. whitehouse.gov
8. Centers for Medicare & Medicaid Services. GLOBE Model. cms.gov. Accessed August 19, 2026.
9. Centers for Medicare & Medicaid Services. GUARD Model. cms.gov. Accessed August 19, 2026.
10. The White House. Lowering Drug Prices by Once Again Putting Americans First. Published April 15, 2025. whitehouse.gov; The White House. Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Published May 12, 2025. whitehouse.gov
11. The White House. Savings from Most-Favored-Nation Drug Pricing Policy. Published May 5, 2026. whitehouse.gov
12. Centers for Medicare & Medicaid Services. GENEROUS Model. Updated July 1, 2026. cms.gov
13. US Food and Drug Administration. Commissioner’s National Priority Voucher (CNPV) Pilot Program. Updated August 14, 2026. fda.gov

Source link

Boresight Ltd (ASX:BST) Share Price Holds Focus on Drone Manufacturing Expansion and Defence Demand

Highlights

• Boresight Ltd (ASX:BST) shares closed at AUD 0.340 on 19 August 2026, declining 2.857% during the session.
• The company develops unmanned aerial systems for defence, security and government customers.
• FY26 unaudited Revenue was reported at AUD 6.7 million, up from AUD 4.36 million in FY25.
• Boresight is expanding United States Manufacturing capacity through a new Facility in Alabama.
• The company remains focused on scaling production and converting defence Demand into commercial opportunities.

Boresight Ltd (ASX:BST) shares closed at AUD 0.340 on 19 August 2026, declining AUD 0.009 or 2.857% compared with the previous close of AUD 0.350. The stock traded between AUD 0.340 and AUD 0.370, with a Volume of 104,610 shares.

The company recorded a Market Capitalisation of AUD 73.15 million, with 209,022,782 ordinary fully paid shares on issue.

The share price movement occurred during the early months following the company’s ASX listing in June 2026. Trading activity remains influenced by limited public trading history and ongoing market assessment of the company’s defence technology operations.

Business Overview and Defence Technology Operations

Boresight designs and manufactures unmanned aerial systems used for defence and security applications. The company develops aerial target drones used for counter-unmanned aerial systems training, testing and defence exercises, along with intelligence, surveillance and reconnaissance (ISR) drone platforms.

The company’s products include target drone systems and camera-equipped drone solutions designed for government, military and industry customers.

Boresight listed on the ASX in June 2026 following an initial public offering that raised approximately AUD 8.0 million.

Manufacturing Expansion and US Strategy

A key development following the listing was Boresight’s expansion of its United States manufacturing capability.

In July 2026, the company announced a Lease for a new manufacturing facility in Huntsville, Alabama. The facility covers approximately 812 square metres and is intended to increase production capacity for the company’s drone products.

The facility is expected to support production of Boresight’s BQ-400 target drone and future products while expanding the company’s ability to service defence customers in the United States.

The company has also continued product development, including updates to its drone range and additional capabilities for defence applications.

Financial Performance and Revenue Growth

Boresight reported unaudited FY26 revenue of AUD 6.7 million, representing growth from AUD 4.36 million in FY25. The company recorded quarterly revenue of AUD 2.44 million during the June 2026 quarter.

The company remains in a growth phase and has not yet reached profitability. Based on available market data, Boresight reported negative trailing earnings per share, with no applicable price-to-earnings ratio.

The company’s financial performance will depend on securing additional defence contracts, scaling manufacturing operations and managing operating costs.

Defence Programs and Customer Development

Boresight has been developing relationships with defence customers through target drone and ISR drone programs.

The company has supplied aerial target drones for defence Training activities and has continued developing products aimed at counter-drone testing and evaluation requirements.

Boresight’s Business model includes recurring demand potential because target drones are designed for training environments where systems may be expended and replaced. However, contract timing and government procurement cycles remain important factors affecting revenue visibility.

Key Areas to Monitor

Future updates will focus on production scale-up, US manufacturing progress, customer contracts and quarterly Cash Flow performance.

The company’s first full-year reporting period as a listed entity will provide additional information on revenue performance, operating costs and cash usage.

Investors will also monitor whether the company can expand its customer base across defence markets while maintaining sufficient funding for manufacturing growth.

Risks and Challenges

Boresight faces risks related to defence procurement cycles, customer concentration, manufacturing expansion, competition and funding requirements. Government contracts can involve long decision periods and uncertain timing. Establishing overseas manufacturing capability may require additional investment, while the company remains loss-making and may require further capital in the future.

The company also operates in a competitive defence technology market where larger international suppliers may have greater resources.

Outlook

Boresight continues to focus on expanding drone manufacturing capacity, developing defence technology products and building customer relationships across international markets. The company’s outlook depends on converting defence demand into contracts, increasing production capability and managing cash requirements during its growth phase.

Progress at the United States manufacturing facility, additional product releases and customer adoption will be key factors influencing future performance.

Conclusion

Boresight’s share price movement on 19 August 2026 occurred as the recently listed defence technology company continued developing its manufacturing footprint and product pipeline. The company has established revenue generation and is expanding into larger markets through increased production capability. However, Boresight remains in an early growth stage, with future performance dependent on contract wins, manufacturing execution and financial management.

Source link

UMass Lowell backs US defence textile manufacturing upgrade

UMass Lowell will play a key role in a 10-year Department of War initiative aimed at modernizing textile manufacturing in the United States to support the defense industry. The FutureTEX award – which includes $36 million in its first year and has a ceiling of $480 million over a decade – brings together industry, government, university and nonprofit partners to advance manufacturing technologies of textiles for military and domestic applications. FutureTEX will champion workforce development and modernization of facilities and equipment to increase U.S. competitiveness.

FutureTEX’s goal is to work with American manufacturing to capitalize on digital infrastructure and other emerging technologies, making the domestic supply network more robust for the defense industrial base. North Carolina State University is spearheading the initiative in partnership with UMass Lowell, Drexel University, Gaston College, Georgia Tech and ISAIC.

UMass Lowell has joined FutureTEX, a 10-year US Department of War initiative to modernise textile manufacturing for defence and domestic applications.
The award includes $36 million in year one and a ceiling of $480 million over a decade.
Partners will target advanced technologies, supply-network resilience, facilities and workforce development.

FutureTEX will empower American textile manufacturing by adopting advanced technologies and techniques to enable manufacturing of new materials and improve capability industry-wide. The initiative is actively recruiting industry partners to be part of the project, and has already received more than 100 letters of support from industry organizations.

“Textile manufacturing is deeply woven into the history of Lowell and UMass Lowell, and today we are building on that legacy by helping shape the future of advanced manufacturing,” said UMass Lowell Chancellor Julie Chen. “FutureTEX adds an exciting new dimension to our strengths in advanced manufacturing and defense, building on the connections among researchers, students and industry partners that we are expanding through the Lowell Innovation Network Corridor.”

NC State is working with Gaston College to establish a nonprofit organization that will assume administrative oversight of FutureTEX. This new institute will be housed at Gaston College’s Kimbrell Campus in Belmont, N.C., with hubs in Lowell, Mass., Raleigh, N.C., Philadelphia, Pa., and Atlanta, Ga.

“FutureTEX is focused on creating a cutting-edge national ecosystem for defense textiles that simply doesn’t exist today,” says David Hinks, chief strategic partnerships officer of FutureTEX and the Prakash Chand Kochhar Dean of NC State’s Wilson College of Textiles. “This will involve commercializing applied research to help American textile manufacturing meet the needs of both the warfighter and the domestic textile industry.”

As a core FutureTEX partner and the initiative’s Massachusetts regional hub, UMass Lowell will connect the consortium with the region’s advanced materials, manufacturing and defense expertise and its extensive industry and government partnerships. The university will manage and expand access to its Fabric Discovery Center, bring faculty and subject-matter experts to FutureTEX projects, help identify and solve manufacturing challenges with industry and government partners, and contribute to workforce-development initiatives, including opportunities for veterans through its existing Veterans Reskilled in Innovative Solutions for Employment (Vets RISE) program.

Through the UMass Lowell Fabric Discovery Center, the university offers capabilities spanning the full materials-to-product pathway, from polymer development and fiber spinning to fabric formation, functional coatings, printed electronics and advanced manufacturing, helping move new textile technologies from research toward production and commercialization.

“FutureTEX gives us an extraordinary opportunity to build on the UMass Lowell Fabric Discovery Center and strengthen the advanced-textiles innovation ecosystem in Massachusetts and across New England,” said UMass Lowell Vice Chancellor for Research, Innovation and Economic Development Anne Maglia. “The future of textiles extends far beyond traditional fabrics and apparel to new materials and manufacturing technologies for aerospace composites, protective systems for our service members, wearable and flexible electronics, medical applications and more. By connecting our researchers, students and facilities with manufacturers and innovators nationwide, FutureTEX will help move ideas into products, strengthen the domestic supply chain and prepare the skilled workforce this industry needs.”

Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged.

Fibre2Fashion News Desk

Source link

Apple opens Advanced Manufacturing Center at massive Houston facility

Cupertino, California-based Apple Inc. unveiled its Advanced Manufacturing Center in the Houston area last week, marking the completion of the second of three facilities the tech giant plans to launch in the city by the end of this year.

The 20,000-square-foot training center will welcome small- and medium-sized businesses for free training and educational sessions to “help accelerate smart manufacturing across America,” according to a release from Apple. Apple opened a similar Apple Manufacturing Academy in Detroit last year.

The AMC is part of Apple’s 500,000-square-foot site in northwest Harris County. It also features a massive manufacturing site for Apple’s advanced AI servers and Mac mini. The facility was originally slated to open in 2026, but Apple began producing its advanced AI servers ahead of schedule in 2025.

The company said it plans to begin manufacturing its Mac mini at the site this year. The move will bring production of the compact desktop computer to the U.S. for the first time.

“In less than nine months, we have invested hundreds of millions of dollars into this Houston facility. We stood up a factory, started production, and shipped the first advanced AI servers off the line. Today, we’re thrilled to open our new Advanced Manufacturing Center, a place where businesses, workers, and students can learn the same innovative processes that we use to make Apple’s most groundbreaking products. And we’re pleased to begin Mac mini production later this year,” Tim Cook, Apple’s CEO, said in the news release. “We believe in American workers and American ingenuity, and we are moving at an incredible pace because we want to build more than great products. We want to build the future of American manufacturing.”

Apple’s Houston expansion is part of a $600 billion commitment the company made to the U.S. in 2025.

The company originally announced plans in February 2025 to open a 250,000-square-foot Houston factory, but doubled the facility’s planned size about a year later. Apple has reported that the factory will employ thousands of workers.

“Houston is grateful to Apple for this significant investment in our city. The Advanced Manufacturing Center will create local jobs and will continue improving the quality of life of Houston residents,” Houston Mayor John Whitmire added in the release. “The AMC also recognizes our city as a growing technology hub and solidifies Houston’s leadership in the manufacturing sector of the United States.”

The opening comes on the heels of New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. officially naming Houston home of its new $2.3 billion, state-of-the-art manufacturing site. Read more here.

Source link

Omnilife Invests US$64 Million in First US Manufacturing Plant

Grupo Omnilife invested US$64 million in its first manufacturing plant in the United States. The move affects the direct-selling and dietary supplement industry and signals a broader shift among Mexico-based multinationals toward dual-market manufacturing strategies. It also reflects growing demand from the US Hispanic population, a segment projected to be the fastest-growing demographic in the country over the next decade  

Grupo Omnilife, the Guadalajara-based direct-selling company known for its nutritional supplements, has inaugurated its first manufacturing plant in the United States. Amaury Vergara, President and General Director, Omnilife, opened the Omnilife Innovation Park in Allen, Texas, which is backed by a US$64 million investment. The facility is expected to produce 1.2 million units annually in its first phase before scaling to 5 million units within three years.

The plant marks the company’s third manufacturing site worldwide, joining existing facilities in Guadalajara and Cali, Colombia. “Texas is strategically key: being a border state that is also centrally located within the United States allows us efficient logistics toward both coasts. In addition, it is home to the region with the largest presence of our independent entrepreneurs,” says Vergara, who leads a multinational with operations in 21 countries. Vergara adds that the site was secured when land values in Allen were still low, ahead of the city’s recent growth surge.

Vergara says the new plant will relieve pressure on the Guadalajara facility, which now operates at 98% of capacity. He expects the Texas site to free up to 18 percentage points of capacity in Guadalajara over the next five years, bringing utilization there down to 80%.

The decision to manufacture in the US follows growing exposure to trade policy risk for Mexican exporters. Mexico’s Ministry of Economy has formally requested a freeze on new US tariffs for the duration of the ongoing joint review of the USMCA, while also pushing Washington to reduce existing duties on automotive and steel products, Minister Marcelo Ebrard said in mid-August. The review, which began July 1, has also raised the possibility of new duties tied to a pending Section 301 investigation into structural manufacturing overcapacity, a probe that could add fresh tariff exposure for sectors including medical devices as early as August.

“Manufacturing in the United States shields us from risks tied to potential increases in import taxes or tariffs on Mexican products, making us highly competitive in the Anglo-Saxon market,” Vergara says. He notes that a possible tariff of up to 25% on supplement imports into the US is not an immediate concern for the company but reinforces the rationale for local production.

Local manufacturing also carries a new dimension. “Manufacturing in the United States opens the door for us to establish partnerships with universities and leading supplement and vitamin research centers worldwide, which require that products be locally manufactured to provide scientific backing,” Vergara says.

The Omnilife Innovation Park sits on a lot of nearly 570,000ft2, with a built area of close to 144,000ft2 across two buildings. Building A will house production, while Building B will initially serve storage and logistics functions, with the design allowing for future expansion of production lines. Vergara said the company aims to reach between 1 million and 2 million units next year, scaling to 5 million units annually within three years.

The US expansion also targets demographic opportunity. “Our main niche is the Hispanic population, the demographic segment with the greatest projected growth in the United States over the next 10 years,” Vergara says. Mexico generates 50% of Omnilife’s revenue, with the remaining 50% coming from the other 21 countries where the company operates.

Source link

US Empire Manufacturing index 20.60 vs 11.00 estimate

The US Empire Manufacturing surver results shows:

• Prior month 15.60
• NY Fed Manufacturing index 20.60 vs 11.00 estimate.

Details:

• New orders 17.3 vs 22.2 last month
• Prices Paid 58.6 vs 52.3 last month
• Prices received 22.7 vs 27.6 last month
• Employment 9.3 vs 11.4 last month.
• Average employee workweek 6.9 versus 2.8 last month
• Shipments 11.7 vs 24.4 last month.
• Unfilled orders 15.5 versus 5.0 last month.
• Delivery time 20.6 versus 13.0 last month.
• Inventories -5.2 versus 4.0 last month.
• Supply availability -13.4 versus -10.0 last month

Looking 6 months forward the survey showed:

• General business conditions 32.1 versus 27.9 last month.
• New orders 37.1 versus 33.2 last month.
• Shipments 33.7 versus 30.6 last month
• prices paid 57.7 versus 53.0 last month.
• Prices received 48.7 versus 41.9 last month.
• Employment 28.2 versus 14.4 last month.
• Average employee workweek 1.0 versus 2.0 last month.
• Capital expenditures 16.5 versus 15.0 last month.
• Supply availability -9.3 versus -8.0 last month.
• Inventories 7.2 versus 10.0 last month.
• Delivery time 7.2 versus -4.0 last month.
• Unfilled orders 19.6 versus -3.0 last month

From NY Fed economic research advisor Richard Deitz:

“New York State manufacturing activity increased at its
fastest pace in over four years in August. Employment continued
to pick up modestly. However, delivery times were substantially
longer and supply availability continued to worsen.”

• New orders remained strong at 17.3, while shipments came in at 11.7, signaling solid demand and production.
• Unfilled orders jumped 11 points to 15.5, indicating a growing backlog.
• Delivery times rose sharply to 20.6, suggesting significant delays.
• Inventories declined during the month.
• Supply conditions deteriorated, with the supply availability index falling to -13.4.

Bottom line: New York manufacturing showed strong growth and healthy demand in August, but rising backlogs, longer delivery times, and worsening supply availability point to increasing supply-chain pressures. That was reflective in the Prices Paid index moving higher, although prices received did fall.

Source link

Hadrian closes $360M revolving credit facility to expand US manufacturing

What’s the deal? Hadrian, the advanced manufacturing startup building automated factories for aerospace and defence, has closed a $360 million revolving credit facility. Morgan Stanley Senior Funding served as lead left arranger and bookrunner.

Joint lead arrangers included Western Alliance Bank, J.P. Morgan, First Citizens Bank, Customers Bank, HSBC Ventures USA, Axos Bank, and Texas Capital Securities.

Why now? The facility lands in August 2026, a week after Hadrian raised a $1.37 billion Series D that valued it at $7.87 billion. The debt will fund manufacturing infrastructure, machinery, and hardware as the company scales output for defence and aerospace customers.

By the numbers: The raise ranks in the top 1% by size among 63 debt rounds by US robotics companies over the past four years.

What’s the endgame? Hadrian is building highly automated factories that combine process engineering, AI, and robotics, aiming to help space and defence manufacturers run full programmes at scale in the US. The company operates four facilities covering just under three million square feet.

Where’s it expanding? Beyond its two Torrance, California sites, Hadrian has launched new factories in Arizona and Alabama, with more in development across the country. The credit line directly supports that growing network as production ramps.

What they’re saying: The facility “underscores the institutional confidence in our strategic direction,” said chief executive officer and founder Chris Power. He added the financing will help build “the industrial capacity the United States needs to remain strategically competitive, while creating thousands of high-quality jobs across the country.”

The signal: Pairing a large equity round with an even swifter debt facility shows how capital-intensive reshoring plays are stacking financing to move fast. For Hadrian, machinery and factory buildout are the constraint — and lenders are betting on defence demand to fill them.

Image credit: Hadrian

Read more: PR Newswire

Source link

Apple opens advanced manufacturing center in Houston, expands its investment in US

Apple is expanding its manufacturing presence in the United States with a new investment of $600 billion that includes the expansion of its plant in Houston. There, the company announced that it will begin manufacturing Mac mini computers before the end of 2026.

The facility is located within the same complex where Apple manufactures its A.I. servers. Tim Cook, the company’s CEO, participated in the groundbreaking ceremony alongside Secretary of Commerce Howard Lutnick, Sen. Ted Cruz (R-Texas), Houston Mayor John Whitmire, Rep. Christian Menefee and Harris County Precinct One Commissioner Rodney Ellis.

The Houston center offers free training for businesses and workers in areas including quality control through machine learning and advanced production techniques. The initiative aims to develop local talent and prepare the workforce for the new demands of technology manufacturing.

Andrés Ignacio Henríquez

“President Trump said we would bring advanced technology manufacturing back to America. Now the Mac mini will be made right here in Houston, Texas. Thank you, Tim and Apple, for your $600 billion commitment to America,” said the secretary of commerce.

Gov. Greg Abbott emphasized that Apple’s expansion reinforces Texas’s position as one of the United States’ leading hubs of innovation: “Apple’s expansion in Houston underscores Texas as the epicenter of American industry and innovation. This new facility will deliver the skills Texans need to excel in advanced manufacturing. We thank Apple for its confidence in the Lone Star State.”

Apple’s expansion comes at a time when the Trump administration is seeking to encourage large technology and manufacturing companies to produce more within the United States. Apple’s case is particularly relevant in this context.

Regarding the investment initiative, called the “American Manufacturing Program,” Apple estimates it will directly hire approximately 20,000 American workers over the program’s four-year duration, primarily in research and development, chip engineering, software, and artificial intelligence.

Source link

Healthcare company plans 600,000-square-foot manufacturing, distribution campus in Lee County – The North State Journal

Sanford in Lee County is set for a major new investment from healthcare company STERIS. (Indy beetle via Wikimedia Commons)

SANFORD — Global healthcare company STERIS plans to invest $600 million in a new manufacturing and distribution campus in Sanford, a project expected to create 335 jobs and further expand Lee County’s growing advanced manufacturing sector.

Gov. Josh Stein announced the project last week, saying the company will establish a 600,000-square-foot Chemistries Manufacturing Center of Excellence that will include manufacturing, research and development, laboratory, warehouse and distribution operations.

The new jobs will have an average annual salary of $68,704, above Lee County’s average wage of $59,903, according to the N.C. Department of Commerce. At full employment, the project could generate an annual payroll of more than $23 million.

“STERIS is making a major investment in North Carolina, which reinforces our state’s reputation as a powerhouse in the life sciences industry,” Stein said. “Decades of excellence in manufacturing and innovation have developed the world-class talent, research and supply chain that continues to attract global companies and drive long-term economic growth across our state.”

Founded in 1985, STERIS provides products and services used in patient care, with a particular focus on infection prevention. The company employs more than 18,000 people at roughly 250 locations in more than 35 countries.

The Sanford facility will consolidate and expand portions of the company’s formulated chemistries manufacturing and distribution operations as STERIS looks to increase U.S. production capacity.

“After extensive analysis of our existing facilities and customer demand, we have decided to make a significant investment in the United States to support our long-term global growth,” STERIS President and CEO Dan Carestio said.

Carestio said the new center will allow the company to accelerate product development, increase capacity, and improve its U.S. manufacturing and distribution network.

“Our customers save lives every day, and with this investment we will be well positioned to support their needs for years to come,” he said.

The project is being supported by a Job Development Investment Grant approved by the state’s Economic Investment Committee.

Under the 12-year agreement, STERIS could receive as much as $3.21 million in reimbursements from the state if it meets required job creation and investment targets. Payments are made only after the departments of Commerce and Revenue verify the company has met those benchmarks.

State officials estimate the project will increase North Carolina’s economy by about $1.8 billion over the life of the grant.

Commerce estimates the project will generate $4.25 in state revenue for every $1 in potential state cost, representing a projected return on investment of 325%.

Because Lee County is classified as a Tier 2 county under the state’s economic development ranking system, as much as $357,000 tied to the grant could also be directed to North Carolina’s Industrial Development Fund Utility Account. The fund helps communities pay for infrastructure improvements used to recruit or expand businesses.

The STERIS announcement adds another large manufacturing investment to the Sanford area, which has attracted a series of life sciences, pharmaceutical and advanced manufacturing projects in recent years.

“STERIS’ decision to make its Center of Excellence in Lee County affirms the region’s emergence as a premier hub for advanced manufacturing,” N.C. Commerce Secretary Lee Lilley said.

The state worked with a broad group of local and regional partners on the project, including the Economic Development Partnership of North Carolina, N.C. Biotechnology Center, Central Carolina Community College, the Sanford Area Growth Alliance, Lee County and the city of Sanford.

Transportation and utility partners include the N.C. Department of Transportation’s Rail Division, North Carolina Railroad Company, Norfolk Southern, TriRiver Water and Duke Energy.

“This landmark investment and expansion mark an exciting new chapter for both the company and our community, creating opportunities for shared growth and long-term economic prosperity,” state Sen. Jim Burgin said.

Source link

Cirrus expands US plant by 30,000 sq ft for aircraft manufacturing

US-based Cirrus has announced a multi-million-dollar, 30,000-square-foot expansion at its Grand Forks facility to meet growing demand for its products across its portfolio.

Cirrus, a global leader in personal aviation, recently opened its expanded manufacturing facility in Grand Forks, North Dakota. This investment advances Cirrus’ mission to ensure manufacturing excellence, safety, quality, and long-term growth.

“This expansion reflects our continued investment in our people, our products, and the Grand Forks community,” said Zean Nielsen, Chief Executive Officer at Cirrus. “By adding more than 30,000 square feet, creating new jobs, and enhancing our workplace for our team members, we’re positioning Cirrus for continued growth.”

“The strong partnerships we’ve built with the City of Grand Forks, the State of North Dakota, the Bank of North Dakota, and the University of North Dakota have given us the confidence to continue investing here, including making Grand Forks the location where we will manufacture composites for the new TRAC10 flight training aircraft.”

Cirrus expands to deliver

Founded in 1984, Cirrus is the recognized global leader in personal aviation and the maker of the best-selling SR Series piston aircraft and the Vision Jet—the world’s first single-engine Personal Jet and the recipient of the Robert J. Collier Trophy.

Since its inception, the company has redefined aviation performance, comfort, and safety with innovations like the Cirrus Airframe Parachute System (CAPS)—the first FAA-certified whole-airframe parachute safety system included as standard equipment on an aircraft, according to a news release.

“To date, worldwide flight time on Cirrus aircraft is over 19 million hours, and over 300 people have returned home safely to their families as a result of the inclusion of CAPS as a standard feature on all Cirrus aircraft,” added Cirrus.

“The company has seven locations in the United States, including Duluth, Minnesota; Grand Forks, North Dakota; Greater Dallas, Texas; Greater Phoenix, Arizona; Greater Orlando, Florida; Knoxville, Tennessee, and Benton Harbor, Michigan.”

The company emphasized the importance of the Grand Forks, North Dakota, location as central to its manufacturing power. Home to about 500 employees, with approximately 80% of them dedicated to direct manufacturing operations, the company called the recent expansion “a significant milestone.” Built to meet current and future production rates, “the expanded facility enables an optimized production layout that streamlines the movement of composite parts throughout the manufacturing process,” according to a news release.

“Grand Forks has played an essential role in Cirrus’ growth and manufacturing strategy for decades,” said Pat Waddick, President of Innovation and Operations at Cirrus in a news release. “Our success starts with our people and our supportive community. This investment allows us to create an even better environment for our team while expanding the capacity and capabilities needed to support our continued growth.”

This growth reflects strong demand and Cirrus’ commitment to both innovation and its employees. The company also highlighted its close partnership with the Grand Forks community, noting that local contributions to the expansion demonstrate a shared commitment to advancing economic growth and manufacturing in the region.

The expanded facility officially opens on August 14. It strengthens Cirrus’ manufacturing network, ensuring the company is well-positioned to meet customer demand while continuing to deliver the quality, innovation, and craftsmanship that define every Cirrus aircraft.

Source link